| human | Q5 |
| P735 | given name | Ruth | Q18014868 |
| Ruth | Q18014868 | ||
| P106 | occupation | researcher | Q1650915 |
| Q51539058 | A comparison of COPD patients with and without ACOS in the ECLIPSE study. |
| Q33913351 | A diVIsive Shuffling Approach (VIStA) for gene expression analysis to identify subtypes in Chronic Obstructive Pulmonary Disease |
| Q35816887 | A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. |
| Q38674540 | A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials |
| Q43251106 | A randomized, placebo-controlled study of the effects of the p38 MAPK inhibitor SB-681323 on blood biomarkers of inflammation in COPD patients |
| Q51461795 | Age-dependent elastin degradation is enhanced in chronic obstructive pulmonary disease. |
| Q34263854 | Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort |
| Q54549439 | An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. |
| Q39023610 | Analysis of nocturnal actigraphic sleep measures in patients with COPD and their association with daytime physical activity |
| Q38604599 | Baseline Severity as Predictor of Change in St George's Respiratory Questionnaire Scores in Trials of Long-acting Bronchodilators with COPD Patients |
| Q37012728 | Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease |
| Q57955681 | Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease |
| Q35637295 | COPD association and repeatability of blood biomarkers in the ECLIPSE cohort |
| Q36600359 | COPD subtypes identified by network-based clustering of blood gene expression |
| Q57955637 | Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes? |
| Q51521679 | Changes in forced expiratory volume in 1 second over time in COPD. |
| Q34149510 | Characterisation of COPD heterogeneity in the ECLIPSE cohort |
| Q44076014 | Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort |
| Q47874561 | Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD. |
| Q38541559 | Circulating soluble receptor for advanced glycation end products (sRAGE) as a biomarker of emphysema and the RAGE axis in the lung |
| Q51616767 | Clinical and prognostic heterogeneity of C and D GOLD groups. |
| Q34471260 | Common genetic variants associated with resting oxygenation in chronic obstructive pulmonary disease |
| Q43802520 | Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort |
| Q37592722 | Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study |
| Q53081631 | Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. |
| Q38604667 | Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD. |
| Q50946397 | Danirixin: A Reversible and Selective Antagonist of the CXC Chemokine Receptor 2. |
| Q39333330 | Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study |
| Q57955800 | Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort |
| Q60917996 | Do sputum or circulating blood samples reflect the pulmonary transcriptomic differences of COPD patients? A multi-tissue transcriptomic network META-analysis |
| Q39367877 | Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. |
| Q57026745 | Effect of the CXCR2 antagonist danirixin on symptoms and health status in COPD |
| Q50043402 | Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype |
| Q50458300 | Eosinophilic inflammation in COPD: prevalence and clinical characteristics |
| Q46178928 | Evaluating the role of inflammation in chronic airways disease: the ERICA study |
| Q58316990 | Evaluation of exhaled breath condensate pH as a biomarker for COPD |
| Q59199233 | Expanded genetic landscape of chronic obstructive pulmonary disease reveals heterogeneous cell type and phenotype associations |
| Q47924133 | Fibrinogen, COPD and mortality in a nationally representative U.S. cohort |
| Q35822156 | Fibrinogen, chronic obstructive pulmonary disease (COPD) and outcomes in two United States cohorts |
| Q36725405 | Fluticasone propionate protects against ozone-induced airway inflammation and modified immune cell activation markers in healthy volunteers |
| Q36000101 | Functional capacity, health status, and inflammatory biomarker profile in a cohort of patients with chronic obstructive pulmonary disease |
| Q41405454 | Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial |
| Q36724956 | Genetic control of gene expression at novel and established chronic obstructive pulmonary disease loci |
| Q30274832 | Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis |
| Q28740314 | Genetics of sputum gene expression in chronic obstructive pulmonary disease |
| Q29416995 | Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease |
| Q46210278 | Heterogeneity of quadriceps muscle phenotype in chronic obstructive pulmonary disease (Copd); implications for stratified medicine? |
| Q41493817 | Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis |
| Q40939340 | Identifying Physical Activity Profiles in COPD Patients Using Topic Models |
| Q53235523 | Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. |
| Q57955696 | Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease |
| Q43800008 | Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies |
| Q64279103 | It's more than low BMI: prevalence of cachexia and associated mortality in COPD |
| Q38169066 | Lessons from ECLIPSE: a review of COPD biomarkers |
| Q40031403 | Long-term Course of Depression Trajectories in Patients With COPD: A 3-Year Follow-up Analysis of the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints Cohort |
| Q42356266 | Longitudinal follow-up of quadriceps strength and function in a COPD cohort after 3 years |
| Q47547470 | Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations |
| Q51614048 | Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. |
| Q58316982 | Metabolic profiling detects biomarkers of protein degradation in COPD patients |
| Q30160748 | Microfibrillar-associated protein 4: A potential biomarker of chronic obstructive pulmonary disease |
| Q37868448 | More than just innate immunity: comparative analysis ofChlamydophila pneumoniaeandChlamydia trachomatiseffects on host-cell gene regulation |
| Q33796180 | Multiple biomarkers predict disease severity, progression and mortality in COPD. |
| Q38452733 | Network Analysis of Lung Transcriptomics Reveals a Distinct B-Cell Signature in Emphysema |
| Q63352630 | New genetic signals for lung function highlight pathways and pleiotropy, and chronic obstructive pulmonary disease associations across multiple ancestries |
| Q34436462 | Non-emphysematous chronic obstructive pulmonary disease is associated with diabetes mellitus |
| Q41420171 | One-year change in health status and subsequent outcomes in COPD. |
| Q34280020 | Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype |
| Q28270421 | Pharmacokinetics, pharmacodynamics and adverse event profile of GSK2256294, a novel soluble epoxide hydrolase inhibitor |
| Q38690517 | Plasma Fibrinogen Qualification as a Drug Development Tool in Chronic Obstructive Pulmonary Disease. Perspective of the Chronic Obstructive Pulmonary Disease Biomarker Qualification Consortium |
| Q35077912 | Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. |
| Q64113226 | Plasma microfibrillar-associated protein 4 is not prognostic of emphysema progression but is associated with cardiovascular disease history and mortality in COPD patients |
| Q57955706 | Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease |
| Q40768309 | Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study |
| Q38007797 | Prospects for the development of effective pharmacotherapy targeted at the skeletal muscles in chronic obstructive pulmonary disease: a translational review |
| Q38771134 | Quantification of Lung PET Images: Challenges and Opportunities |
| Q64270436 | Real-world use of rescue inhaler sensors, electronic symptom questionnaires and physical activity monitors in COPD |
| Q44226689 | Reply: minimal or maximal clinically important difference: using death to define MCID. |
| Q43974929 | Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results |
| Q38604602 | Responder Analyses for Treatment Effects in COPD Using the St George's Respiratory Questionnaire |
| Q29416987 | Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis |
| Q35183636 | SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans |
| Q42715750 | Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis |
| Q39780802 | Sarcopenic Obesity, Functional Outcomes, and Systemic Inflammation in Patients With Chronic Obstructive Pulmonary Disease |
| Q35042489 | Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease |
| Q51159286 | Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. |
| Q45152589 | Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization |
| Q38604595 | Socioeconomic Status as a Determinant of Health Status Treatment Response in COPD Trials |
| Q33995697 | Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study |
| Q40076551 | St George's Respiratory Questionnaire Score Predicts Outcomes in Patients with COPD: Analysis of Individual Patient Data in the COPD Biomarkers Qualification Consortium Database |
| Q57955820 | Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease |
| Q47366696 | Systemic Markers of Adaptive and Innate Immunity are Associated with COPD Severity and Spirometric Disease Progression |
| Q43779676 | Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease |
| Q58316980 | Targeted metabolomics identifies perturbations in amino acid metabolism that sub-classify patients with COPD |
| Q37559927 | The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium |
| Q38109909 | The COPD Biomarker Qualification Consortium (CBQC). |
| Q38604605 | The COPD Biomarkers Qualification Consortium Database: Baseline Characteristics of the St George's Respiratory Questionnaire Dataset |
| Q47715266 | The St. George's Respiratory Questionnaire Appendix to the Food and Drug Administration Draft Guidance on COPD: Why a Small Step Forward Is So Important |
| Q54981842 | The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. |
| Q35669293 | The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects |
| Q43875548 | The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study |
| Q36535812 | The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD. |
| Q64097216 | Type IV collagen turnover is predictive of mortality in COPD: a comparison to fibrinogen in a prospective analysis of the ECLIPSE cohort |
| Q46438856 | Validation of the human ozone challenge model as a tool for assessing anti-inflammatory drugs in early development |
| Q33687879 | Variants in FAM13A are associated with chronic obstructive pulmonary disease |
| Q43966274 | p38 mitogen-activated protein kinase is not activated in the quadriceps of patients with stable chronic obstructive pulmonary disease |
Search more.